ClinicalTrials.gg
CompletedNCT00035789Updated Apr 14, 2011

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

A Phase 3 interventional study of Entecavir in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 31 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2011-04-14.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Started
2001
with 1 other
Phase 3
13 of 64
none open now
Registered
2nd of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is one of 2 that started in 2001, is one of 13 in phase 3, and was the 2nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of chronic infection;
  • HBeAg negative, anti-HBeAb positive;
  • Absence of coinfection with (HIV), virus (HCV) or hepatitis D virus (HDV);
  • Absence of other forms of liver disease e.g., alcoholic, , biliary disease;
  • Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment

Interventions

06

Study locations

31 sites
  • Local Investigator
    Birmingham, Alabama, United States
  • Local Investigator
    Tucson, Arizona, United States
  • Local Investigator
    La Jolla, California, United States
  • Local Investigator
    Los Angeles, California 90048, United States
  • Local Investigator
    Orange, California, United States
  • Local Investigator
    San Francisco, California, United States
  • Local Investigator
    Farmington, Connecticut, United States
  • Local Investigator
    Miami Beach, Florida, United States
  • Local Investigator
    Atlanta, Georgia 30322, United States
  • Local Investigator
    Honolulu, Hawaii, United States
  • Local Investigator
    Chicago, Illinois 60622, United States
  • Local Investigator
    Iowa City, Iowa, United States
  • Local Investigator
    Kansas City, Kansas, United States
  • Local Investigator
    Dundalk, Maryland, United States
  • Local Investigator
    Worcester, Massachusetts, United States
  • Local Investigator
    Ann Arbor, Michigan, United States
  • Local Investigator
    Royal Oak, Michigan, United States
  • Local Investigator
    St. Paul, Minnesota, United States
  • Local Investigator
    Manhasset, New York, United States
  • Local Investigator
    New York, New York, United States
  • Local Investigator
    Rochester, New York, United States
  • Local Investigator
    Charlotte, North Carolina, United States
  • Local Investigator
    Cleveland, Ohio, United States
  • Local Investigator
    Philadelphia, Pennsylvania, United States
  • Local Investigator
    Pittsburgh, Pennsylvania, United States
  • Local Investigator
    Providence, Rhode Island, United States
  • Local Investigator
    Nashville, Tennessee 37211, United States
  • Local Investigator
    Dallas, Texas, United States
  • Local Investigator
    Fairfax, Virginia, United States
  • Local Investigator
    Richmond, Virginia, United States
  • Local Investigator
    Seattle, Washington, United States
07

References and documents

Publications

  • Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1011-20. doi: 10.1056/NEJMoa051287. Erratum In: N Engl J Med. 2006 Apr 27;354(17):1863. PubMed 16525138 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of May 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2002
First posted
May 6, 2002
Start
Nov 2001
Primary completionActual
May 2005
CompletionActual
May 2005
Results delay requested
Jan 28, 2010
Last update
Apr 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00035789
First posted
May 6, 2002
Start date
Nov 2001
Primary completion
May 2005
Completion
May 2005
Last update
Apr 14, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion